Capital Research Global Investors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$248M Sell
2,061,571
-50,571
-2% -$5.84M 0.04% 220
2025
Q4
$222M Sell
2,112,142
-198,473
-9% -$18.6M 0.04% 218
2025
Q3
$194M Sell
2,310,615
-1,151,654
-33% -$94.9M 0.04% 226
2025
Q2
$274M Buy
3,462,269
+311,535
+10% +$24.8M 0.05% 192
2025
Q1
$283M Sell
3,150,734
-1,322,651
-30% -$123M 0.06% 178
2024
Q4
$445M Buy
4,473,385
+2,431,430
+119% +$251M 0.09% 144
2024
Q3
$232M Buy
2,041,955
+681
+0% +$80.9K 0.05% 200
2024
Q2
$253M Sell
2,041,274
-184
-0% -$23.7K 0.06% 197
2024
Q1
$269M Buy
2,041,458
+1,633
+0.1% +$201K 0.06% 202
2023
Q4
$222M Sell
2,039,825
-459
-0% -$47.6K 0.05% 220
2023
Q3
$210M Buy
2,040,284
+1,141
+0.1% +$123K 0.06% 224
2023
Q2
$235M Buy
2,039,143
+391
+0% +$44.4K 0.06% 211
2023
Q1
$217M Buy
2,038,752
+858
+0% +$92.6K 0.06% 218
2022
Q4
$226M Buy
2,037,894
+977
+0% +$99.9K 0.07% 202
2022
Q3
$175M Buy
2,036,917
+57
+0% +$5.09K 0.06% 214
2022
Q2
$186M Sell
2,036,860
-116
-0% -$10.3K 0.06% 224
2022
Q1
$167M Buy
2,036,976
+1,029
+0.1% +$81.1K 0.04% 257
2021
Q4
$156M Sell
2,035,947
-275,548
-12% -$21.9M 0.03% 272
2021
Q3
$174M Buy
2,311,495
+1,236
+0.1% +$94K 0.04% 263
2021
Q2
$180M Sell
2,310,259
-3,300,114
-59% -$245M 0.04% 256
2021
Q1
$413M Sell
5,610,373
-248,204
-4% -$18.3M 0.1% 176
2020
Q4
$457M Buy
5,858,577
+2,621
+0% +$200K 0.12% 161
2020
Q3
$464M Sell
5,855,956
-1,162
-0% -$91K 0.14% 146
2020
Q2
$432M Buy
5,857,118
+7,074
+0.1% +$533K 0.14% 144
2020
Q1
$429M Sell
5,850,044
-637,913
-10% -$50.1M 0.17% 117
2019
Q4
$563M Buy
6,487,957
+1,164
+0% +$95.6K 0.17% 120
2019
Q3
$521M Sell
6,486,793
-1,049,887
-14% -$84.1M 0.17% 129
2019
Q2
$603M Buy
7,536,680
+3,934
+0.1% +$301K 0.19% 119
2019
Q1
$598M Sell
7,532,746
-4,717,978
-39% -$353M 0.19% 111
2018
Q4
$893M Buy
12,250,724
+2,036
+0% +$144K 0.31% 70
2018
Q3
$829M Buy
12,248,688
+4,716,378
+63% +$300M 0.24% 87
2018
Q2
$436M Buy
7,532,310
+3,208
+0% +$181K 0.12% 150
2018
Q1
$391M Buy
7,529,102
+17,580
+0.2% +$949K 0.11% 162
2017
Q4
$403M Sell
7,511,522
-1,498
-0% -$83K 0.12% 153
2017
Q3
$459M Sell
7,513,020
-696
-0% -$42.2K 0.14% 146
2017
Q2
$459M Sell
7,513,716
-1,464
-0% -$89.1K 0.14% 146
2017
Q1
$456M Buy
7,515,180
+4,177
+0.1% +$253K 0.14% 149
2016
Q4
$422M Buy
7,511,003
+2,775
+0% +$162K 0.14% 155
2016
Q3
$447M Sell
7,508,228
-1,070
-0% -$62.6K 0.15% 145
2016
Q2
$413M Buy
7,509,298
+12,760
+0.2% +$679K 0.14% 149
2016
Q1
$378M Hold
7,496,538
0.13% 159
2015
Q4
$378M Hold
7,496,538
0.13% 159
2015
Q3
$353M Hold
7,496,538
0.13% 163
2015
Q2
$407M Hold
7,496,538
0.13% 166
2015
Q1
$411M Hold
7,496,538
0.14% 154
2014
Q4
$406M Hold
7,496,538
0.14% 160
2014
Q3
$424M Sell
7,496,538
-419,200
-5% -$23.5M 0.15% 156
2014
Q2
$437M Hold
7,915,738
0.15% 142
2014
Q1
$429M Hold
7,915,738
0.15% 144
2013
Q4
$378M Sell
7,915,738
-3,144,000
-28% -$144M 0.14% 154
2013
Q3
$502M Hold
11,059,738
0.2% 123
2013
Q2
$490M Buy
+11,059,738
New +$494M 0.21% 119

Other funds holding MRK

Capital Research Global Investors's MRK Position: Q1 2026 in Review

Capital Research Global Investors reduced its Merck (MRK) stake by 2.4% in Q1 2026, selling an estimated $5.84M and leaving 2,061,571 shares worth $248M. The position accounts for 0.04% of the portfolio, ranked #220.

Capital Research Global Investors first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $893M in Q4 2018. 3,783 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Capital Research Global Investors held 2,061,571 shares of Merck worth $248M as of Q1 2026.
  • Capital Research Global Investors sold 50,571 Merck shares in Q1 2026, an estimated $5.84M.
  • Merck made up 0.04% of Capital Research Global Investors's portfolio in Q1 2026, its #220 holding.
  • Capital Research Global Investors first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Capital Research Global Investors's Merck position peaked at $893M in Q4 2018.
  • 3,783 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.